Scarica l'app Stockscreener
33.22
9.74%
-3.585
Precedente Chiudi:
$36.80
Aprire:
$36.83
Volume 24 ore:
384.66K
Relative Volume:
0.81
Capitalizzazione di mercato:
$920.42M
Reddito:
$3.25M
Utile/perdita netta:
$-116.80M
Rapporto P/E:
-10.89
EPS:
-3.05
Flusso di cassa netto:
$-98.17M
1 W Prestazione:
-4.94%
1M Prestazione:
+15.13%
6M Prestazione:
+299.22%
1 anno Prestazione:
+356.25%
Intervallo 1D:
$32.98
$37.38
Intervallo di 1 settimana:
$32.98
$38.45
Portata 52W:
$5.6652
$42.39
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Nome
Rapt Therapeutics Inc
Settore
Industria
Telefono
(650) 489-9000
Indirizzo
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Confronta RAPT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
33.22 | 1.02B | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-27 | Iniziato | Guggenheim | Buy |
| 2025-10-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-09-26 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-07-30 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2025-05-22 | Ripresa | H.C. Wainwright | Buy |
| 2024-12-26 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-11-13 | Downgrade | Stifel | Buy → Hold |
| 2024-11-11 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-11-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-05-14 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-05-10 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-05-10 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-02-22 | Downgrade | UBS | Buy → Neutral |
| 2024-02-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-02-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-02-21 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-02-20 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2024-02-16 | Iniziato | Evercore ISI | Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2023-09-14 | Iniziato | Berenberg | Buy |
| 2023-08-09 | Iniziato | Stifel | Buy |
| 2023-06-15 | Iniziato | Barclays | Overweight |
| 2023-01-04 | Iniziato | Guggenheim | Buy |
| 2022-12-01 | Iniziato | Goldman | Buy |
| 2022-09-21 | Iniziato | CapitalOne | Overweight |
| 2022-05-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-12-09 | Iniziato | JP Morgan | Overweight |
| 2021-08-12 | Iniziato | SVB Leerink | Outperform |
| 2021-06-21 | Iniziato | Piper Sandler | Overweight |
| 2020-06-01 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-04-13 | Iniziato | ROTH Capital | Buy |
| 2019-11-25 | Iniziato | BMO Capital Markets | Outperform |
| 2019-11-25 | Iniziato | UBS | Buy |
| 2019-11-25 | Iniziato | Wells Fargo | Outperform |
Mostra tutto
Rapt Therapeutics Inc Borsa (RAPT) Ultime notizie
Rapt Therapeutics (NASDAQ:RAPT) Stock Price Down 9.2%Should You Sell? - MarketBeat
RAPT Therapeutics, Inc. (NASDAQ:RAPT) surges 5.3%; individual investors who own 34% shares profited along with institutions - Yahoo Finance
Rapt Therapeutics (NASDAQ:RAPT) Trading Up 4.9%Here's Why - MarketBeat
BVF Inc. IL Trims Holdings in Rapt Therapeutics $RAPT - MarketBeat
RAPT Therapeutics Announces Major Public Stock Offering - MSN
Rapt Therapeutics $RAPT Shares Sold by Redmile Group LLC - MarketBeat
Can RAPT Therapeutics Inc. (0RA) stock deliver strong annual returnsMarket Risk Summary & Growth Focused Investment Plans - Newser
Published on: 2025-12-04 13:14:54 - Newser
How RAPT Therapeutics Inc. (0RA) stock compares with tech leadersPortfolio Return Summary & Reliable Volume Spike Alerts - Newser
How robust is RAPT Therapeutics Inc. (0RA) stock financial positionVolume Spike & Risk Managed Trade Strategies - Newser
Does RAPT Therapeutics Inc (RAPT) offer a good opportunity for investors? - Setenews
Can RAPT Therapeutics Inc. (0RA0) stock sustain margin levels2025 Biggest Moves & Fast Moving Market Watchlists - Newser
What macro factors could drive RAPT Therapeutics Inc. (0RA0) stock higherRecession Risk & Fast Exit/Entry Strategy Plans - Newser
Why RAPT Therapeutics Inc. (0RA) stock is trending on social mediaFed Meeting & Safe Capital Allocation Plans - Newser
How RAPT Therapeutics Inc. (0RA0) stock performs in easing cyclesRisk Management & Technical Pattern Based Buy Signals - Newser
Published on: 2025-12-02 05:12:24 - Newser
Can RAPT Therapeutics Inc. (0RA) stock ride next bull market cycle2025 Big Picture & Growth Oriented Trade Recommendations - Newser
RAPT Therapeutics announces planned departure of chief medical officer - Investing.com India
RAPT Therapeutics announces planned departure of chief medical officer By Investing.com - Investing.com Nigeria
RAPT Therapeutics Announces CMO Departure - TipRanks
RAPT Therapeutics Announces Departure of Chief Medical Officer - TradingView
Are Smart Investors Making the Right Decision? RAPT Therapeutics Inc (RAPT) - Setenews
RAPT Therapeutics, Inc.'s (NASDAQ:RAPT) Market Cap Touched US$830m Last Week, Benefiting Both Individual Investors Who Own 34% as Well as Institutions - 富途牛牛
While institutions invested in RAPT Therapeutics, Inc. (NASDAQ:RAPT) benefited from last week's 17% gain, individual investors stood to gain the most - simplywall.st
Form 8-KCurrent report - ADVFN
Rapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash Position - MSN
Foresite Capital Management VI LLC Decreases Stock Holdings in Rapt Therapeutics $RAPT - MarketBeat
RAPT Therapeutics Shares Surge on Institutional Confidence and Clinical Progress - AD HOC NEWS
Rapt Therapeutics (NASDAQ:RAPT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Rapt Therapeutics (NASDAQ:RAPT) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
RAPT rockets 180% on licensing deal, $150M private placement (update) - MSN
RAPT SEC FilingsRapt Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Will RAPT Therapeutics Inc. stock outperform Nasdaq index2025 Market Overview & Fast Moving Market Watchlists - newser.com
Why RAPT Therapeutics Inc. stock appeals to dividend seekersWeekly Trade Recap & Weekly Breakout Watchlists - newser.com
Why analysts remain bullish on RAPT Therapeutics Inc. stockTrade Analysis Report & AI Powered Buy/Sell Recommendations - newser.com
Can RAPT Therapeutics Inc. stock deliver sustainable ROE2025 Geopolitical Influence & Fast Entry Momentum Trade Alerts - newser.com
D pipelineJuly 2025 Levels & Verified Chart Pattern Trade Signals - newser.com
Is RAPT Therapeutics Inc. (0RA) stock a good hedge against inflationRisk Management & Daily Risk Controlled Trade Plans - newser.com
How strong is RAPT Therapeutics Inc. stock revenue growthWeekly Profit Recap & Verified Momentum Watchlists - newser.com
Is RAPT Therapeutics Inc. stock a buy before product launches2025 Biggest Moves & Long-Term Investment Growth Plans - newser.com
How supply shortages influence RAPT Therapeutics Inc. (0RA0) stockJuly 2025 Decliners & Fast Exit and Entry Strategy Plans - newser.com
How RAPT Therapeutics Inc. (0RA0) stock stacks up against competitorsJuly 2025 Selloffs & Risk Controlled Daily Plans - newser.com
Rapt Therapeutics Inc Azioni (RAPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):